Dexdor: a new hospital-only sedative

Continuous cardiac monitoring is required during dexmedetomidine infusion | SCIENCE PHOTO LIBRARY

Dexdor (dexmedetomidine) is licensed for adult patients in intensive care who require sedation not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).

Dexmedetomidine is a selective alpha-2 receptor agonist. It exerts its sedative effect through decreased firing of the locus coeruleus, the predominant noradrenergic nucleus in the brainstem. Dexmedetomidine has minimal respiratory depressive effects.

Dexdor must be given by intravenous infusion using a controlled infusion device.

View Dexdor drug record

Further information: Orion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...